Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Cipla
Citi
AstraZeneca
US Army
Chinese Patent Office
Harvard Business School
UBS
Dow

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 088895

« Back to Dashboard

NDA 088895 describes BENZTROPINE MESYLATE, which is a drug marketed by Fresenius Kabi Usa, Hikma Farmaceutica, Luitpold, Navinta Llc, Anda Repository, Aspen Global Inc, Epic Pharma Llc, Invagen Pharms, Lannett Holdings Inc, Leading Pharma Llc, Oxford Pharms, Pliva, Quantum Pharmics, Usl Pharma, and Vintage, and is included in twenty-seven NDAs. It is available from thirty-one suppliers. Additional details are available on the BENZTROPINE MESYLATE profile page.

The generic ingredient in BENZTROPINE MESYLATE is benztropine mesylate. There are five drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the benztropine mesylate profile page.
Summary for 088895
Tradename:BENZTROPINE MESYLATE
Applicant:Lannett Holdings Inc
Ingredient:benztropine mesylate
Patents:0
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 088895

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Apr 11, 1985TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Baxter
Cerilliant
Moodys
Express Scripts
AstraZeneca
Chinese Patent Office
Novartis
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot